Inactive Instrument

Other languages Crescita Therapeutics Inc. Other OTC

Equities

CRRTF

CA2258471028

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

Crescita Therapeutics Reports Q4 Net Loss of $0.01 Per Share	Mar. 13
Crescita Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 13
Crescita Therapeutics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 13
Crescita Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08
Crescita Therapeutics Inc. announces an Equity Buyback for 1,821,616 shares, representing 8.94% of its issued share capital.	23-08-29
Crescita Therapeutics Inc. authorizes a Buyback Plan.	23-08-28
Crescita Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09
Crescita Therapeutics Inc. Announces Launch of Topical Anaesthetic Pliaglis(R) in Europe in Its European Core Markets Including Germany, the United Kingdom and Ireland	23-06-01
Crescita Therapeutics Q1 Revenue was $4.6 Million; Cites Cash Balance of $10.3M	23-05-11
Crescita Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11
Crescita Therapeutics Reports Q4 Revenue of $6.03 Million, EPS of $0.06	23-03-15
Crescita Therapeutics Inc. acquired unknown minority stake in Akyucorp Ltd. for CAD 0.06 million.	23-03-14
Crescita Therapeutics Reports Q3 Revenue of $6 Million; EPS C$0.01; Cash Balance of $10.7 Million	22-11-09
Crescita Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-09
Crescita Therapeutics Reports Q2 Revenue of $6.5 Million	22-08-10
Crescita Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-10
Crescita Therapeutics Q1 Loss of $0.02 Per Share	22-05-11
Crescita Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-11
Crescita Therapeutics Reports Q4 EPS C$0.04; Revenue was $7.562 Million; Expands Pliaglis Licenses to 32 New Countries	22-03-23
Crescita Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-23

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Crescita Therapeutics Inc. Other OTC

Equities

CRRTF

CA2258471028

Other languages

Filters